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Abstract
Background: The negative feedback system is an important physiological regulatory mechanism controlling
angiogenesis. Soluble vascular endothelial growth factor (VEGF) receptor-1 (sFlt-1), acts as a potent endogenous
soluble inhibitor of VEGF- and placenta growth factor (PlGF)-mediated biological function and can also form
dominant-negative complexes with competent full-length VEGF receptors.
Methods and results: Systemic overexpression of VEGF-A in mice resulted in significantly elevated circulating sFlt-
1. In addition, stimulation of human umbilical vein endothelial cells (HUVEC) with VEGF-A, induced a five-fold
increase in sFlt-1 mRNA, a time-dependent significant increase in the release of sFlt-1 into the culture medium and
activation of the flt-1 gene promoter. This response was dependent on VEGF receptor-2 (VEGFR-2) and
phosphoinositide-3’-kinase signalling. siRNA-mediated knockdown of sFlt-1 in HUVEC stimulated the activation of
endothelial nitric oxide synthase, increased basal and VEGF-induced cell migration and enhanced endothelial tube
formation on growth factor reduced Matrigel. In contrast, adenoviral overexpression of sFlt-1 suppressed
phosphorylation of VEGFR-2 at tyrosine 951 and ERK-1/-2 MAPK and reduced HUVEC proliferation. Preeclampsia is
associated with elevated placental and systemic sFlt-1. Phosphorylation of VEGFR-2 tyrosine 951 was greatly
reduced in placenta from preeclamptic patients compared to gestationally-matched normal placenta.
Conclusion: These results show that endothelial sFlt-1 expression is regulated by VEGF and acts as an autocrine
regulator of endothelial cell function.
Background
Vascular endothelial growth factor-A (VEGF-A) is a
multifunctional cytokine induced by hypoxic stress [1].
It plays a pivotal role in many aspects of embryonic car-
diovascular development, including formation of blood
vessels, cardiac morphogenesis, and development of the
nervous system [2-6]. Loss and gain of function studies
in mice indicate that VEGF-A levels have to be main-
tained within a narrow range to ensure proper cardio-
vascular development and embryo survival [7-9]. It has
been shown that the effects of VEGF-A can be deleter-
ious if uncontrolled. Over-expression of VEGF in experi-
mental animals increases the leakiness of blood vessels,
which may lead to severe edema, loss of limb and death
[10,11]. Excess VEGF-A expression in skeletal muscle
results in the induction of vascular tumors (hemangio-
mas) [12-14], whereas loss of VEGF-A activity due to
increased production of its natural antagonist, sFlt-1
(soluble VEGF receptor-1/sVEGFR-1), as in preeclamp-
sia, reduces angiogenesis [15]. Thus, homeostasis
requires mechanisms to regulate the functional activity
of VEGF-A.
Soluble Flt-1 is generated by alternative splicing of the
fms-like tyrosine kinase (flt-1) gene [16], and binds to
all isoforms of VEGF-A and placenta growth factor
(PlGF) with high affinity [16,17]. It acts as a potent solu-
ble inhibitor of both VEGF-A and PlGF-mediated biolo-
gical activities [18] and can also form dominant-negative
complexes with competent full-length VEGF receptors
[16]. In pregnancies complicated with preeclampsia,
sFlt-1 levels are elevated [15,19-21]. Maternal serum
levels of sFlt-1 are elevated five weeks prior to the onset
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of preeclampsia [22], supporting the premise that sFlt-1
is a key factor responsible for the clinical manifestation
of this disorder [23]. The demonstration that sFlt-1 is
fundamental to the clinical onset of preeclampsia [24]
highlights the importance of understanding the intracel-
lular mechanism underlying its regulation and release in
endothelial cells. Recently it was shown that autocrine
VEGF signaling is required for vascular homeostasis
[25]. Here we demonstrate that endothelial sFlt-1
expression is regulated by VEGF and sFlt-1 is an auto-
crine regulator of endothelial cell function.
Materials and methods
Reagents
Recombinant growth factors were purchased from RELIA-
Tech (Brauschweig, Germany). Rabbit polyclonal antibo-
dies against phospho- endothelial nitric oxide synthase
(eNOS) at serine-1177 (p-eNOSSer1177), phospho-ERK-1/-
2 MAPK and phospho-VEGF receptor-2 (VEGFR-2) tyro-
sine-951 antibodies were purchased from Calbiochem
(Nottingham, UK). Small inhibitory RNAs (siRNA) and
oligonucleotide primers were purchased from Eurogentec
(Southampton, UK). Luciferase reporter assay and cDNA
synthesis kits were from Promega (Southampton, UK). All
other cell culture reagents and chemicals were obtained
from Sigma Aldrich (Poole, UK).
Placental tissues
Human placental tissue was obtained from normal preg-
nancies and gestationally-matched pregnancies compli-
cated by preeclampsia. Preeclampsia was defined as
blood pressure > 140/90 mm Hg on at least two conse-
cutive measurements and proteinuria of at least 300 mg
per 24 hours. Informed consent was obtained from the
patients and the study had the approval of the South
Birmingham Ethical Committee (Birmingham, UK).
Cell Culture
Primary human umbilical vein endothelial cells
(HUVEC) were isolated and cultured as described [26].
Cells were used at passage two or three for experiments
and serum-starved in endothelial cell serum-free med-
ium (Gibco-BRL, UK) supplemented with 0.2% bovine
serum albumin for 24 hours prior to stimulation.
Adenoviral gene transfer
The recombinant, replication-deficient adenoviruses
encoding sFlt-1 (Ad-sFlt-1) VEGF (Ad-VEGF) and
PTEN (Ad-PTEN) were used as described previously
[27-29].
Quantitative Real-Time PCR
Sample preparation and real-time PCR was performed as
described previously [30]. Briefly, mRNA was prepared
using TRIzol and DNase-1 digestion/purification on
RNAeasy columns (Qiagen), and reverse transcribed with
the cDNA Synthesis Kit (Promega). Triplicate cDNA
samples and standards were amplified in SensiMix con-
taining SYBR green (Quantace) with primers specific for
sFlt-1 [31]. The mean threshold cycle (CT) was normal-
ized to b-actin and expressed relative to control.
siRNA knock-down of sFlt-1
Two siRNA sequences to the unique 3’ sequence of sFlt-
1 (sFlt-1 A sense: 5’-TAACAGUUGUCUCAUAUCAtt-3’
and antisense: 5’-UGAUAUGAGACAACUGUUAtt-3’;
sFlt-1 B sense: 5’-UCUCGGAUCUCCAAAUUUAtt-3’
and antisense 5’-UAAAUUUGGAGAUCCGAGAtt-3’)
were designed using the Dharmacon siDESIGN tool
[32]. HUVEC (~ 1 × 106 cells) were electroporated with
~ 3 μg of sFlt-1, or a universal control siRNA (Dharma-
con) using the HUVEC kit II and Amaxa nucleofector
(Amaxa GmbH, Cologne, Germany) as described [30].
Transduction of chimeric VEGF Receptors in HUVEC
A chimeric VEGF/epidermal growth factor (EGF) receptor
comprising the intracellular and transmembrane domains
of VEGFR-2 fused to the extracellular domain of the
human EGF receptor [33]. EGF does not bind to VEGF
receptors, therefore, it does not activate the endogenous
VEGF receptors. EGDR and its tyrosine-to-phenylalanine
mutants (EGDR-Y951F) were generated and cloned into
the pMMP retroviral vector, and retrovirus-containing cell
supernatant was harvested and used immediately to infect
HUVEC [33]. Following 16 hours of incubation, the med-
ium was replaced with fresh growth medium and the
HUVEC were used 48 hours after infection.
Nitric oxide (NO) Release
Total NO in conditioned media was assayed as nitrite,
the stable breakdown product of NO, using a Sievers
NO chemiluminescence analyzer (Analytix, Sunderland,
UK) as described previously [33].
Tube Formation Assay
The formation of capillary-like structures was examined
on growth factor-reduced Matrigel in 24-well plates as
described previously [33]. Tube formation was quanti-
fied by measuring the total tube length in five random
x200 power fields per well using a Nikon phase-contrast
inverted microscope with Image ProPlus image analysis
software (Media Cybernetics, Silver Spring, USA). Mean
total tube length was calculated from three independent
experiments performed in duplicate.
flt-1 gene promoter activity assay
A 1.3 Kb fragment of the human flt-1 gene correspond-
ing to -1214 to +155 bp relative to the first exon in the
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pGL2 luciferase vector (Promega) was used to determine
flt-1 promoter activity [34]. Briefly, porcine aortic
endothelial cells (PAEC) were transfected with the flt-1
promoter-reporter construct using Exgen 500 (Fermen-
tas, UK) and the cell lysates assayed as described pre-
viously [34].
Western Blotting
Cells lysates were immunoblotted as described pre-
viously [33]. Membranes were probed with rabbit poly-
clonal antibodies against phospho-eNOS-Ser1177, anti-
ERK-1/-2 or anti-VEGFR-2 phosphotyrosine-951 at 4°C
overnight. Proteins were visualised using the ECL detec-
tion kit (Amersham-Pharmacia, UK).
sFlt-1 ELISA
Soluble Flt-1 (sFlt-1) levels in culture supernatants were
measured as previously described [30].
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were used for
immunohistochemistry as previously described [15].
Statistical analysis
All data are expressed as mean ± SEM. Statistical com-
parisons were performed using one-way ANOVA fol-
lowed by the Student-Newman-Keuls test as
appropriate. Statistical significance was set at a value of
p < 0.05.
Results and Discussion
VEGF-A stimulates sFlt-1 release
To evaluate the capacity of VEGF-A to regulate the
secretion of its negative regulator, sFlt-1, HUVEC were
incubated with VEGF-A and the conditioned media
assayed for sFlt-1 by ELISA. VEGF-A stimulated a con-
centration and time dependent increase in the release of
sFlt-1 from HUVEC that reached a maximum at 20 ng/
ml and 48 hours, respectively (Figure 1a and 1b). Con-
sistent with these findings, qPCR revealed a greater than
five-fold increase in sFlt-1 mRNA after 22 hours of
VEGF-A stimulation (Figure 1c). In addition, VEGF-A
induced flt-1 gene promoter activity in porcine aortic
endothelial cells transfected with a flt-1 promoter luci-
ferase construct (Figure 1d). Incubation of cells with
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Figure 1 VEGF stimulates sFlt-1 release from endothelial cells in vitro, and in vivo. (a) VEGF stimulated sFlt-1 release from HUVEC in a
concentration-dependent manner. sFlt-1 was measured, in the culture medium, by ELISA, following a 24-hour incubation. (b) Time course of
VEGF (20 ng/ml) induced sFlt-1 release from HUVEC. (c) VEGF induced an increase in sFlt-1 mRNA levels in HUVEC as determined by qPCR and,
(d) flt-1 promoter activity in porcine aortic endothelial cells by luciferase assay. (e) Cyclohexamide (10 μg/ml) inhibits VEGF-induced sFlt-1 protein
synthesis after 24 hours of treatment. (f) Mouse plasma levels of sFlt-1 five days post intravenous injection with an adenovirus encoding VEGF
(Ad-VEGF) or control (Ad-bgal). Data are expressed as mean (± SEM) or representative of three or more independent experiments performed in
triplicate. **P < 0.01; ***P < 0.001 vs. control.
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cycloheximide abrogated the VEGF-A induced response
(Figure 1e), which coupled with the fact that there is a
negligible release with VEGF-A after two hours of sti-
mulation, indicates that sFlt-1 secretion is due to de
novo protein synthesis and not release from intracellular
vesicles. Adenoviral-mediated overexpression of VEGF-
A in mice caused an eight-fold increase in circulating
sFlt-1 levels (Figure 1f), demonstrating, in vivo, that an
increase in VEGF-A results in a concomitant rise in cir-
culating sFlt-1 levels, presumably to compensate for ele-
vated VEGF bioactivity.
Activation of VEGFR-2, mediates the release of sFlt-1
To identify the VEGF receptors involved in the release
of sFlt-1, HUVEC were stimulated with either VEGF-A
(binds VEGFR-1 and VEGFR-2), or PlGF-1 (binds
VEGFR-1) or VEGF-E (binds VEGFR-2). PlGF-1 showed
no effect on sFlt-1 release, whereas VEGF-E stimulated
similar levels of sFlt-1 release to those induced by
VEGF-A (Figure 2a), suggesting that release of sFlt-1 is
mediated by VEGFR-2. Preincubation of endothelial
cells with SU1498, a VEGFR-2 selective inhibitor,
blocked the VEGF-A induced sFlt-1 release (Figure 2b),
confirming the importance of this receptor for the
response.
VEGF stimulated sFlt-1 production, is mediated via PI3K
To investigate the role of the PI3K pathway in VEGF-A-
induced sFlt-1 release, PI3K activity was inhibited
through overexpression of PTEN (Phosphatase and Ten-
sin homolog deleted on chromosome Ten), which
dephosphorylates phosphatidylinositol 3,4,5-triphosphate
and has been shown to reduce VEGF-mediated signaling
and cellular function [28,35]. HUVEC were infected
overnight with an adenovirus encoding PTEN (PTEN
(wt)) or a control adenovirus (CMV) and stimulated
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Figure 2 VEGF-A-induced sFlt-1 release requires VEGFR-2 and the PI3K pathway. (a) sFlt-1 release from HUVEC 24 hours after incubation
with PlGF-1 (20 ng/ml), VEGF-A (20 ng/ml) and VEGF-E (20 ng/ml). (b) sFlt-1 release from HUVEC after incubation with SU1498 (10 μM), a VEGFR-
2 tyrosine kinase inhibitor, prior to addition of VEGF-A (20 ng/ml) for 24 hours. (c) sFlt-1 release from HUVEC infected with an adenovirus
encoding PTEN (PTEN (wt)) or control adenovirus (CMV) prior to stimulation with VEGF-A (20 ng/ml) for 24 hours. Western blot demonstrating
decreased PTEN expression in HUVEC infected with Ad-PTEN(wt) compared with Ad-CMV control (insert). (d) sFlt-1 release from HUVEC after
incubation with LY294002 (10 μM), a PI3K inhibitor, prior to addition of VEGF-A (20 ng/ml) for 24 hours. (e) LY294002 prevented the VEGF-A-
induced flt-1 promoter activity in porcine aortic endothelial cells, assayed by luciferase reporter assay. Data are expressed as mean (± SEM) or
representative of three or more independent experiments performed in triplicate. **P < 0.01 vs. control.
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with VEGF-A for 24 hours. Inhibition of PI3K activity
by PTEN overexpression led to a significant decrease in
sFlt-1 release (Figure 2c). Furthermore, pre-incubation
of HUVEC with LY294002, a pharmacological PI3K
inhibitor, also attenuated the VEGF mediated release of
sFlt-1 (Figure 2d) and of flt-1 gene promoter activity
(Figure 2e).
Loss of sFlt-1 promotes angiogenesis
Adenoviral-mediated overexpression of sFlt-1 in
HUVEC inhibited endothelial cell proliferation (Figure
3a) and MAP kinase ERK-1/-2 phosphorylation (Figure
3a insert). Subsequently, to test whether knockdown of
sFlt-1 would promote endothelial cell proliferation,
HUVEC were transfected with two synthetic siRNA
sequences targeted to the unique carboxyl-terminus
region of sFlt-1. sFlt-1 siRNA transfection resulted in a
substantial reduction in the release of sFlt-1 from
HUVEC after 24 hours (Figure 3b). Endothelial cell pro-
liferation was significantly increased (Figure 3c) and
interestingly, sFlt-1 knockdown also led to a concomi-
tant increase in VEGFR-2 phosphorylation at tyrosine
951 (Y951) (Figure 3d). In addition, sFlt-1 siRNA
increased both basal and VEGF-A-mediated endothelial
cell migration (Figure 4a) and tube formation on Matri-
gel (Figure 4b and 4c). VEGF stimulates eNOS activity
and NO release [23,36] to mediate angiogenesis [33,37],
thus we predicted that loss of sFlt-1 would increase
eNOS phosphorylation in HUVEC. Phosphorylation of
eNOS (ser1177) was significantly increased in cells lack-
ing sFlt-1 (Figure 4d). These data provide direct evi-
dence that sFlt-1 is itself a negative regulator of
endothelial function. It is likely that sFlt-1 sequesters
VEGF and PlGF to maintain a physiological steady state
until angiogenesis is required, at which point this system
must be overridden.
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Figure 3 sFlt-1 inhibits endothelial cell proliferation and VEGF receptor phosphorylation. (a) Cell proliferation after 48 hours of treatment
in HUVEC infected with an adenovirus encoding sFlt-1 (Ad-sFlt1) or b-galactosidase control (Ad-bGal). Western blot demonstrating decreased
Erk1/2 phosphorylation in HUVEC infected with Ad-sFlt-1 compared with Ad-b-gal control (insert). (b) Dramatic reduction of sFlt-1 release from
HUVEC 24 hours after transfection with sFlt-1 siRNA. (c) Cell proliferation after 48 hours in sFlt-1 siRNA transfected HUVEC. (d) Western blot
showing VEGF receptor-2 (VEGFR-2) phosphorylation at tyrosine 951 in HUVEC transfected with sFlt-1, or control siRNA. VEGFR-2 and b-actin
were used as a loading control. Data are expressed as mean (± SEM) or representative of three or more independent experiments performed in
triplicate. **P < 0.01 vs. control.
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Excess sFlt-1 inhibits VEGFR-2 Y951 phosphorylation
Activation of VEGFR-2 leads to an increase in eNOS
expression and activation,[38] which is essential for
neovascularisation [37]. A recent study showed that
mutation of VEGFR-2 Y951 to phenylalanine caused a
significant reduction in VEGF-induced angiogenesis
[33]. As preeclampsia is associated with elevated pla-
cental [15] and circulating [22] sFlt-1 and placental
sFlt-1 inhibits angiogenesis [15], we speculated that
elevated free sFlt-1 would lead to a reduction of
VEGFR-2 phosphorylation in preeclamptic placenta.
Using the EGFR-chimeric receptor system we show
that mutation of Y951 to phenylalanine resulted in
over 50% reduction in NO release (Figure 5a) and
overexpression of sFlt-1 in endothelial cells abrogated
phosphorylation of VEGFR-2 Y951 (Figure 5b). To
assess whether VEGFR-2 phosphorylation was reduced
in preeclamptic placenta, that express elevated sFlt-1,
we undertook immunohistochemical analysis for phos-
pho-VEGFR-2 Y951. Overall, phosphorylation of
VEGFR-2 Y951 was greatly reduced in the preeclamp-
tic placenta compared to gestationally-matched, nor-
mal placenta (Figure 5c). Together, these findings
indicate that increased levels of sFlt-1 have a negative
effect on VEGFR-2 tyrosine phosphorylation, which in
turn would lead to concomitant inhibition of down-
stream function and signaling and compromise mater-
nal vascular homeostasis and placental angiogenesis.
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Figure 4 Loss of sFlt-1 enhances angiogenesis and eNOS phoshorylation. (a) VEGF (20 ng/ml) induced an increase in cell migration of
HUVEC transfected with sFlt-1 siRNA compared with control siRNA using a modified Boyden chamber assay. (b) VEGF-induced capillary-like tube
formation and (c) quantification of mean total tube length per field of view after six hours treatment in HUVEC transfected with sFlt-1 siRNA or
control. (d) Representative Western blot showing eNOS phosphorylation at serine 1177 (p-eNOS (S1177)) in HUVEC transfected with soluble (sFlt-
1) or control siRNA. b-actin was used as a loading control. Data are expressed as mean (± SEM) or representative of three or more independent
experiments performed in triplicate. **P < 0.01 vs. control.
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Conclusions
Endothelial cell sFlt-1 expression is regulated by VEGF
and sFlt-1 is an autocrine regulator of endothelial cell
function.
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